Our results show that the three tumours responding to volasertib are partially responsive to palbociclib and PDX with primary resistance to palbociclib were also resistant to volasertib, suggesting that cell cycle is the common determinant of response to CDK4/6 and PLK1 inhibitors. The gene discussed is PLK1; the disease is neoplasm.